The effect of Agnugol on painful symptoms of endometriosis and quality of life

Phase 3

Recruiting

• Conditions: endometriosis.; Female pelvic inflammatory disorders in other diseases classified elsewhere; N74.8

• Registration Number: IRCT20180404039187N11
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 70

Inclusion Criteria

Women with endometriosis whose disease has been diagnosed based on clinical symptoms and imaging (sonography) as well as previous documented evidence of endometriosis.
Women with symptomatic endometriosis.
Women who are in the age range of 18-49 years.
They have not taken anti-inflammatory or hormonal drugs in the last three months.
Don't have endometrial hypoplasia or neoplasia.
Women who are married and sexually active.

Exclusion Criteria

Women who are allergic to medicinal plants, especially the Lamiaceae family.
Women suffering from gallstones, jaundice due to biliary obstruction and acute biliary colic.
Women with digestive diseases.
Women who suffer from inflammatory diseases or diseases associated with immune system defects such as rheumatoid arthritis, lupus, multiple sclerosis, etc.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life of endometriosis patients. Timepoint: before investigation and 8 weeks after investigation. Method of measurement: questionnaire 30-EHP.;Symptoms of pelvic pain and gynecology. Timepoint: before investigation and 8 weeks after investigation. Method of measurement: questionnaire ENDOPAIN-4D.

Secondary Outcome Measures

Name	Time	Method
Pain. Timepoint: the first 3 days of the next 3 menstrual cycles. Method of measurement: VAS ruler.